Page 2288 - Hematology_ Basic Principles and Practice ( PDFDrive )

2033.e2 Part XII Hemostasis and Thrombosis

46. Franchini M, Tagliaferri A, Mengoli C, et al: Cumulative inhibitor 66. Gilles JG, Arnout J, Vermylen J, et al: Anti-factor VIII antibodies of
incidence in previously untreated patients with severe haemophilia hemophiliac patients are frequently directed towards nonfunctional
A treated with plasma-derived versus recombinant factor VIII con- determinants and do not exhibit isotypic restriction. Blood 82:2452,
centrates: a critical systematic review. Crit Rev Oncol Hematol 81:82, 1993.
2012. 67. Hofbauer CJ, Whelan SF, Hirschler M, et al: Affinity of FVIII-specific
47. Maclean PS, Richards M, Williams M, et al: Chalmers EA for the antibodies reveals major differences between neutralizing and non-
Paediatric Working Party of the UKHCDO. Treatment related factors neutralizing antibodies in humans. Blood 125:1180–1188, 2015.
and inhibitor development in children with severe haemophilia A. 68. Hay CR, Ollier W, Pepper L, et al: HLA class II profile: A weak deter-
Haemophilia 17:282, 2011. minant of factor VIII inhibitor development in severe haemophilia A.
48. Peerlinck K, Arnout J, Di Giambattista M, et al: Factor VIII inhibitors UKHCDO Inhibitor Working Party. Thromb Haemost 77:234, 1997.
in previously treated haemophilia A patients with a double virus- 69. Oldenburg J, Picard JK, Schwaab R, et al: HLA genotype of patients
inactivated plasma derived factor VIII concentrate. Thromb Haemost with severe haemophilia A due to intron 22 inversion with and without
77:80, 1997. inhibitors of factor VIII. Thromb Haemost 77:238, 1997.
49. Peerlinck K, Arnout J, Gilles JG, et al: A higher than expected incidence 70. Lavigne-Lissalde G, Schved JF, Granier C, et al: Anti-factor VIII
of factor VIII inhibitors in multitransfused haemophilia A patients antibodies: A 2005 update. Thromb Haemost 94:760, 2005.
treated with an intermediate purity pasteurized factor VIII concentrate. 71. Astermark J, Wang X, Oldenburg J, et al on behalf of the MIBS Study
Thromb Haemost 69:115, 1993. Group: Polymorphisms in the CTLA-4 gene and inhibitor develop-
50. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al: A sudden ment in patients with severe haemophilia A. J Thromb Haemost 5:263,
increase in factor VIII inhibitor development in multitransfused hemo- 2007.
philia A patients in The Netherlands. Dutch Hemophilia Study Group. 72. Astermark J, Oldenburg J, Pavlova A, et al: Polymorphisms in the
Blood 81:2180, 1993. IL-10 but not in the IL-1β and IL-4 genes are associated with
51. Giles AR, Rivard GE, Teitel J, et al: Surveillance for factor VIII inhibi- inhibitor development in patients with hemophilia A. Blood 107:3167,
tor development in the Canadian Hemophilia A population following 2006.
the widespread introduction of recombinant factor VIII replacement 73. Astermark J, Donfield SM, Gomperts ED, et al: The polygenic nature
therapy. Transfus Sci 19:139, 1998. of inhibitors in hemophilia A: results from the Hemophilia Inhibitor
52. van den Berg HM, Chalmers EA: Clinical prediction models for inhibi- Genetics Study (HIGHS) Combined Cohort. Blood 121:1445–1454,
tor development in severe hemophilia A. J Thromb Haemost 7(Suppl 2013.
1):98–102, 2009. 74. Miao CH: Immunemodulation for inhibitors in haemophilia A: the
53. Gouw SC, van den Berg HM, Fischer K, et al: for the RODIN Study important role of Treg cells. Expert Rev Hematol 3:469, 2010.
Group. Intensity of factor VIII treatment and inhibitor development 75. Lenting PJ, van Mourik JA, Mertens K: The life cycle of coagula-
in children with severe hemophilia A: the RODIN study. Blood tion factor VIII in view of its structure and function. Blood 92:3983,
121:4046–4056, 2013. 1998.
54. Halimeh S, Bidkingmaier C, Heller C, et al: Risk factors of high-titre 76. Saenko EL, Ananyeva NM, Tuddenham EG, et al: Factor VIII—Novel
Inhibitor development in children with hemophilia A: results of a insights into form and function. Br J Haematol 119:323, 2002.
cohort study. Biomed Res Int 901975:2013. 77. Saenko EL, Scandella D: The acidic region of the factor VIII light chain
55. Fisher K, Lassila R, Peyvandi F, et al on behalf of the EUHASS: Inhibi- and the C2 domain together form the high affinity binding site for von
tor development in haemophilia according to concentrate. Four-year Willebrand factor. J Biol Chem 272:18007, 1997.
results from the European Haemophilia Safety Surveillance project. 78. Lollar P, Hill-Eubanks DC, Parker CG: Association of the factor
Thromb Haemost 113:2015. VIII light chain with von Willebrand factor. J Biol Chem 263:10451,
56. Peyvandi F, Mannucci PM, Garagiola I, et al: A randomized trial of 1988.
FVIII and neutralizing antibodies in hemophilia A. N Engl J Med 79. Shima M, Scandella D, Yoshioka A, et al: A factor VIII neutralizing
374:2054–2064, 2016. monoclonal antibody and a human inhibitor alloantibody recognizing
57. Hay CR, Palmer BP, Chalmers EA, et al: The incidence of factor VIII epitopes in the C2 domain inhibit factor VIII binding to von Wil-
inhibitors in severe haemophilia A following a major switch from lebrand factor and to phosphatidylserine. Thromb Haemost 69:240,
full-length to B-domain-deleted factor VIII: a prospective cohort 1993.
comparison. Haemophilia 21:219–226, 2015. 80. Saenko EL, Scandella D: A mechanism for inhibition of factor VIII
58. Carcao MD: More on: Intensive factor VIII exposure and inhibi- binding to phospholipid by von Willebrand factor. J Biol Chem
tor development in mild hemophilia A. J Thromb Haemost 2:677, 270:13826, 1995.
2004. 81. Saenko EL, Shima M, Gilbert GE, et al: Slowed release of thrombin-
59. Eckhardt CL, van Velzen AS, Petrs M, et al: for the INSIGHT Study cleaved factor VIII from von Willebrand factor by a monoclonal and a
Group. Factor VIII gene (F8) mutation and risk of inhibitor develop- human antibody is a novel mechanism for factor VIII inhibition. J Biol
ment in nonsevere hemophilia A. Blood 122:1954–1962, 2013. Chem 271:27424, 1996.
60. Ivaskevicius V, Goldman G, Horneff S, et al: Inhibitor development 82. Barrow RT, Healey JF, Jacquemin MG, et al: Antigenicity of putative
and management in three non-severe haemophilia A patients with phospholipid membrane-binding residues in factor VIII. Blood 97:169,
T295A variant. Hamostaseologie 34(S1):9–12, 2014. 2001.
61. Hay CR, Dimichele DM: The principal results of the International 83. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibi-
Immune Tolerance Study: a randomized dose comparison. Blood tion by human antibodies. Antibodies that bind to the factor VIII light
119:1335, 2012. chain prevent the interaction of factor VIII with phospholipid. J Clin
62. White GC, 2nd, Kempton CL, Grimsley A, et al: Cellular immune Invest 83:1978, 1989.
responses in hemophilia: Why do inhibitors develop in some, but not 84. Lollar P: Molecular characterization of the immune response to factor
all hemophiliacs? J Thromb Haemost 3:1676, 2005. VIII. Vox Sang 83:403, 2002.
63. Aalberse RC: Shcuurman J. IgG4 breaking the rules. Immunology 85. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al: Catalytic activ-
105:9–19, 2002. ity of antibodies against factor VIII in patients with hemophilia A. Nat
64. Reipert BM: Risky business of inhibitors: HLA haplotypes, gene Med 5:1044, 1999.
polymorphisms, and immune responses. Hematology Am Soc Hematol 86. Lacroix-Desmazes S, Bayry J, Misra N, et al: The prevalence of pro-
Educ Program 2014:372, 2014. teolytic antibodies against factor VIII in hemophilia A. N Engl J Med
65. Boylan B, Rice AS, Dunn AL, et al: Characterization of the anti- 346:662, 2002.
factor VIII immunoglobulin profile in patients with hemophilia A by 87. Lacroix-Desmazes S, Wootla B, Dasgupta S, et al: Catalytic IgG from
use of fluorescenc-based immunoassay. J Thromb Haemost 13:47–53, patients with hemophilia A inactivate therapeutic factor VIII. J Immunol
2015. 177:1355, 2006.